1. Introduction {#sec1}
===============

Obesity results from an energy imbalance and is now considered a serious and global health risk by the World Health Organization (WHO). It is associated with health problems like dyslipidemia, hypertension, fatty liver disease, diabetes mellitus, cancers, osteoarthritis, and asthma \[[@B1], [@B2]\]. In 2014, WHO reported that more than 1.9 billion adults, 18 years and above, stated as overweight and of these about more than 31% were obese \[[@B3]\]. Moreover, WHO predicted that this number will be elevated to approximately 3.3 billion by 2030 (about 1.7 times) \[[@B4]\]. According to this current trend, the economic burden of obesity (direct and indirect health care costs including health monitoring, nutritional supplements, and surgical management) is expected to grow every year. To date, orlistat (Xenical) approved by FDA, relatively effective drug for long-term treatment of obesity, exerts the drug efficacy through inhibition of pancreatic lipase enzyme and prevents the absorption of approximately 30% of dietary fat \[[@B5]\]. However, it is limited in its use due to severe gastrointestinal side effects. Herein, the prevention of the obesity may decrease the incidence of obesity-related diseases and lead to reducing immoderate costs and undesirable side effects. Hence, the recent obesity targets are focused on innoxious and therapeutic natural products. An inhibition of the dietary fat absorption is one of the common approaches in the effort to decrease an excessive energy intake \[[@B6]\].

Pancreatic lipase enzyme (triacylglycerol acylhydrolase) secreted from pancreas is a key enzyme related to the dietary triglycerides absorption and catalyzes the digestion of dietary triglycerides \[[@B7]\]. Among various lipases, pancreatic lipase performs the hydrolysis of 50--70% of total dietary fats \[[@B8]\]. The reduction of fat absorption through pancreatic lipase inhibition is known to benefit the regulation of obesity \[[@B9]\]. Hydrolysis activity of pancreatic lipase is maintained by Ser152, Asp176, and His263 amino acids; particularly, Ser152 is responsible for lipolysis activity \[[@B10]\].

PCM is herbal formulation of*Diospyros kaki* fruit (*Diospyros kaki* Thunb.) and*Citrus unshiu* peel (*Citrus unshiu* S. Marcov.). Both of these herbs are the most well-known traditional herbal medicines, frequently used to treat obesity \[[@B11]--[@B13]\]. Peel of*Citrus unshiu*, which is a seedless and easy-peeling citrus fruit, has been used for traditional herbal medicine in East-Asia including Korea.*Diospyros kaki* fruit contains a number of bioactive compounds, including polyphenols (especially tannins), carotenoids, flavonoids, vitamins, minerals, and dietary fiber \[[@B14], [@B15]\]. Particularly, tannins exert several biological effects, which involve antioxidant, anti-inflammatory, antitumor, antihypertensive, and antidiabetic activities \[[@B16], [@B17]\]. In addition,*Citrus unshiu* peel contains many phytochemicals such as hesperidin, naringin, and nobiletin \[[@B18]\]. The biological and multiple compounds of two herbs,*Diospyros kaki* fruit or*Citrus unshiu* peel, performed a pharmacological effect such as hypocholesterolemic \[[@B19]\], antiadipogenic \[[@B20]\], anti-inflammatory \[[@B21]\], antioxidant \[[@B22]\], antitumor \[[@B13]\] effects.

To the best of our knowledge, no study has previously investigated the antiobesity effect of*Diospyros kaki* fruit and*Citrus unshiu* peel mixture extract,*in vitro* or*in vivo*. Therefore, the present study aims to investigate the inhibition property on porcine pancreatic lipase*in vivo* and changes in body weight and serum lipid parameters and visceral fat weight on an experimental model of obesity.

2. Materials and Methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Porcine pancreatic lipase (Type II), orlistat, morpholinepropanesulfonic acid (MOPS), Tris-HC1,*p*-nitrophenyl butyrate (*p*-NPB), 2,2-diphenyl-1-picrylhydrazyl (DPPH), and 2,2′-azino-bis-diammonium salt (ABTS) were purchased from Sigma-Aldrich Co. (St Louis, MO, USA). Ethylenediaminetetraacetic acid (EDTA) was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Viscozyme® was purchased from Novozymes (Denmark). All other reagents were of biochemical grade.

2.2. Preparation of the Mixture Extract {#sec2.2}
---------------------------------------

A unripe*Diospyros kaki* fruit (*Diospyros kaki* Thunb.) was harvested in Gyeongsangbuk-do Agricultural Research & Extension Services (Sangju, Korea) and a dried*Citrus unshiu* peel (*Citrus unshiu* S. Marcov.) was purchased from MSC Co., Ltd. (Yangsan, Korea). Each 500 kg was selected and extracted with 5 times of water and boiled in 100°C for 2 h. And then enzyme decomposition was carried out for 15 h. Next, enzyme (Viscozyme) was inactivated in 90°C for 30 min \[[@B24]\]. After filtration using the diatomite, the extracts were concentrated till 0 bx. The concentrated extracts added dextrin and were sterilized in 95°C for 30 min. The sterilized extracts were freeze-dried and powered by a grinder.

2.3. Experimental Animals and Treatment {#sec2.3}
---------------------------------------

Male healthy 4-week-old ICR mice (about 30--32 g) were purchased from Orient (Gyeonggi-do, Korea). Each mouse was kept at room temperature (22 ± 3°C) and humidity (55 ± 5%) with a 12-h light/dark cycle. The experiments were approved by the Ethics Committee of Animal Experimentation of the University of Daegu Haany. The mice were allowed free access to laboratory pellet chow and water ad libitum. After adaptation (1 week), all experimental mice except normal mice (*n* = 8) were fed with 60% high-fat diet (HFD; Diet 12492, Research Diets, Inc., New Brunswick, NJ, USA) for 5 days to adapt to a feed. Thereafter, ICR mice (*n* = 32) fed 60% HFD were randomly divided into four groups (*n* = 8 in each group): HFD control group, orlistat group (60 mg/kg/day), and two PCM treatment groups (50 and 200 mg/kg/day). The normal group is supplied with a normal feed and the rest of the groups are supplied with 60% HFD until the experimental end. The normal and HFD control groups were given water using a stomach tube, while the drug treatment groups were orally given orlistat or PCM daily using a stomach tube for 6 weeks. After administration for 6 weeks, each mouse was etherized after fasting for 12 h. The blood was immediately centrifuged at 1,500 ×g for 10 min at 4°C. Serum triglyceride and total cholesterol were conducted spectrophotometrically using commercially available kits (Wako Pure Chemical Industries, Ltd., Osaka, Japan). HDL-cholesterol is measured using a commercial kit from Asan Pharm Co., Ltd. (Hwaseong-si, Korea, Cat. AM203). LDL-cholesterol levels are calculated though TG, TC, and HDL levels: $$\begin{matrix}
{\text{LDL-cholesterol  level}\left( {{{mg}/{dL}}} \right)} \\
{\mspace{1800mu} = \frac{\left\lbrack {\text{TC} - \left\lbrack \text{HDL-cholesterol} \right\rbrack - \text{TG}} \right\rbrack}{5}.} \\
\end{matrix}$$

2.4. DPPH Radical Scavenging Activity of PCM {#sec2.4}
--------------------------------------------

Antioxidant activity determination of PCM was performed by the DPPH radical scavenging according to the method of Park et al. \[[@B25]\]. 100 *μ*L of an ethanolic solution of PCM (blank: 100 *μ*L of ethanol) was added to 100 *μ*L of an ethanolic solution of DPPH (60 *μ*M) using 96-well plate. The ascorbic acid (standard sample) was prepared for eight concentrations (0.5, 1, 2, 5, 10, 20, 50, and 100 *μ*g/mL). The PCM was prepared for six concentrations (5, 10, 20, 50, 100, and 200 *μ*g/mL). The reaction mixture was incubated in the dark at 25°C for 30 min. The optical density was determined using a microplate reader model infinite M200 PRO (Tecan, Austria). The mixture was measured spectrophotometrically at 540 nm. The antioxidant activity of each sample was expressed in terms of IC~50~ (micromolar concentration required to inhibit DPPH radical formation by 50%, calculated from the log-dose inhibition curve). The radical scavenging activity was calculated as a percentage using the following equation:$$\begin{matrix}
{\text{DPPH  radical  scavenging  activity}\left( {\%} \right)} \\
{\mspace{1800mu} = \left\lbrack { 1 - \left\lbrack {\frac{A_{sample}}{A_{blank}}} \right\rbrack} \right\rbrack \times 100.} \\
\end{matrix}$$

2.5. ABTS Radical Scavenging Activity of PCM {#sec2.5}
--------------------------------------------

ABTS radical scavenging activity of the different extracts was measured according to the modified method of Re et al. \[[@B26]\]. ABTS stock solution was dissolved in water to 7.4 mM concentration. The ABTS radical cation (ABTS) was produced by reacting ABTS stock solution with 2.45 mM potassium persulfate and allowing the mixture to stand for 14 h at room temperature in the dark. The ABTS solution was diluted with ethanol to obtain an absorbance of 0.70 ± 0.02 at 750 nm. After adding 95 *μ*L of diluted ABTS solution (*A* ~750 nm~ = 0.70 ± 0.02) to 5 *μ*L of sample, the mixture was left at room temperature for 15 min in the dark. The absorbance at 750 nm was measured using a microplate reader model infinite M200 PRO (Tecan, Austria). The blank was prepared in the same manner, except distilled water was used instead of the sample. The radical scavenging activity was calculated as a percentage using the following equation:$$\begin{matrix}
{\text{ABTS  radical  scavenging  activity}\left( {\%} \right)} \\
{\mspace{1800mu} = \left\lbrack { 1 - \left\lbrack {\frac{A_{sample}}{A_{blank}}} \right\rbrack} \right\rbrack \times 100.} \\
\end{matrix}$$

2.6. Measurement of Porcine Pancreatic Lipase Inhibitory {#sec2.6}
--------------------------------------------------------

Pancreatic lipase activity was modified from the method previously reported by Kim et al. \[[@B27]\]. Briefly, an enzyme buffer was prepared by the addition of 6 *μ*L of a solution of porcine pancreatic lipase (Sigma-Aldrich) in buffer containing 10 mM MOPS (morpholinepropanesulfonic acid) and 1 mM EDTA, pH 6.8, to 169 *μ*L Tris buffer (100 mM Tris-HC1 and 5 mM CaCl~2~, pH 7.0). Then, either 20 *μ*L of PCM at the test concentration (100, 250, 500, and 1000 *μ*g/mL) or orlistat (0.1, 0.25, 0.5, and 1 *μ*g/mL) was mixed with 175 *μ*L enzyme buffer and incubated for 15 min at 37°C with 5 *μ*L of the substrate solution \[10 mM*p*-NPB (*p*-nitrophenyl butyrate) in dimethylformamide\]. The enzymatic reactions were allowed to proceed for 35 min at 37°C. Lipase activity was determined by measuring the hydrolysis of*p*-NPB into*p*-nitrophenol. Increase in light absorption at 405 nm was measured using a microplate reader, model infinite M200 PRO (Tecan, Austria). Inhibition of lipase activity was expressed as the percentage decrease in OD when porcine pancreatic lipase was incubated with the test compounds. Lipase inhibition (%) was calculated according the following formula:$$\begin{matrix}
{\text{Inhibition}\left( {\%} \right) = 100 - \left\lbrack {\frac{\left\lbrack {B - b} \right\rbrack}{\left\lbrack {A - a} \right\rbrack}\ast 100} \right\rbrack,} \\
\end{matrix}$$where *A* is the activity without inhibitor, *a* is the negative control without inhibitor, *B* is the activity with inhibitor, and *b* is the negative control with inhibitor. The results were expressed as an average (*n* = 4).

2.7. Total Phenolic and Flavonoid Contents {#sec2.7}
------------------------------------------

The total phenolic content of PCM was quantified by mild modification from the method of Folin-Ciocalteu \[[@B28]\]. 10 *μ*L PCM and distilled water 790 *μ*L were shaken well and then mixed with 50 *μ*L of Folin-Ciocalteu\'s reagent for 1 min. After that 150 *μ*L of 20% sodium carbonate solution (Na~2~CO~3~) was added and the mixture was shaken for 2 h at 20°C. Finally, the absorbance of the resulting color was measured at 765 nm. The total phenolic content was expressed as mg gallic acid equivalents per gram extract. Values presented are the average of three measurements. Flavonoid was extracted and quantified by adaptation of the method of Lister et al. \[[@B29]\]. PCM 50 *μ*L and 500 *μ*L diethylene glycol were mixed well. And then 1 N NaOH 5 *μ*L was added and the mixture was incubated for 1 h at 37°C. Finally, the absorbance of the resulting color was measured at 420 nm. The flavonoid content was expressed as mg naringin equivalents per gram extract. Values presented are the average of three measurements.

2.8. Statistical Analysis {#sec2.8}
-------------------------

Data are expressed as mean ± SEM. Statistical comparisons were assessed by one-way ANOVA followed by Dunnett\'s multiple comparison test (SPSS 18.0 for Windows, SPSS Inc., USA) and values of *p* \< 0.05 were considered significant. Also, simple regression analysis was performed to investigate the correlation between DPPH radical scavenging and ABTS radical scavenging using the Microsoft Excel 2010 statistical package.

3. Results and Discussion {#sec3}
=========================

Antioxidant agents from natural herbs have received a potent attention since they are safe and lesser toxic \[[@B30]\]. This study was performed to determine the antioxidant activity of PCM through DPPH and ABTS radical scavenging activity \[[@B31]\]. Antioxidant activity is expressed in terms of IC~50,~ and a lower IC~50~ value corresponds to a larger scavenging activity. IC~50~ (*μ*g/mL) represents half maximal concentration of tested compounds to scavenge DPPH and ABTS radical. As shown in Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}, IC~50~ of DPPH radical scavenging activity of PCM was found to be 117.46 ± 4.89 *μ*g/mL and IC~50~ value of ascorbic acid (positive control) as a positive control was 1.26 ± 0.02 *μ*g/mL. The calculated IC~50~ value of PCM against the ABTS radical was determined to be 120.04 ± 1.67 *μ*g/mL and IC~50~ value of ascorbic acid as a positive control was 2.27 ± 0.19 *μ*g/mL (Figures [1(c)](#fig1){ref-type="fig"} and [1(d)](#fig1){ref-type="fig"}).

Moreover, the phenolic compound or flavonoid performs as another antioxidant agent by chelating redox-active metal ions, inactivating lipid free radical chains, and avoiding the hydroperoxide conversions into reactive oxyradicals \[[@B31], [@B32]\]. Total phenolic content was measured as gallic acid equivalents (GAE) with reference to standard curve (*y* = 0.023*x* + 0.30 and *R* ^2^ = 0.997) and was found to be 29.90 ± 0.14 mg GAE/g of PCM extract. The flavonoid content was 18.33 ± 0.08 mg naringin equivalent (NE)/g of PCM extract, respectively, with reference to standard curve (*y* = 0.0195*x* + 0.04 and *R* ^2^ = 0.9999). The total phenolic content was expressed as gallic acid equivalents and flavonoid content was expressed as rutin or naringin equivalents varied according to extract condition or developmental stage. However, young persimmon used in this experiment is higher than old persimmon used by a different researcher in two contents based on our current study \[[@B34], [@B35]\].

Dietary fats are mainly comprised of mixed triglycerides about 90% and need to be hydrolyzed by the various lipases for their absorption. The main human lipases to digest dietary fats include lingual, gastric, and pancreatic lipases \[[@B36]\]. Among these lipases, pancreatic lipase is responsible for the hydrolysis of 50--70% of dietary fats to fatty acids (FA) and monoglycerides (MG). These are released by lipid hydrolysis and form mixed micelles with bile salts, cholesterol, and lysophosphatidic acid. And then mixed micelles are absorbed into enterocytes where resynthesis of TG happens. Finally, triglyceride is stored in adipocytes as the major source of energy \[[@B8]\]. Recently, new approaches for the treatment of obesity tried to reduce energy intake through gastrointestinal mechanisms, without altering any vital mechanisms. Pancreatic lipase inhibition is one of such attempts and many researchers focused on the potential efficacy of natural products as antiobesity agents \[[@B38]\]. In the*in vitro* experiment, the ability of extract had condensed tannins as an inhibitor of pancreatic lipase seems to be well demonstrated \[[@B39]\]. In our current study, the obtained result showed that PCM inhibited pancreatic lipase activity with IC~50~ of 507.01 *μ*g/mL compared to orlistat with IC~50~ of 0.218 *μ*g/mL ([Figure 2](#fig2){ref-type="fig"}). PCM was not more effective than positive control (orlistat). However, the pancreatic lipase inhibitory effect of PCM was superior to those when various dietary plants were screened by Conforti et al. \[[@B40]\].

Ultimately, obesity causes abdominal visceral fat and weight change due to HFD. An excessive accumulation of fat in the abdominal viscera is associated with the increase of serum TG, TC, and LDL, which are related to hyperlipidemia \[[@B41]\]. To evaluate the effects of PCM on HFD-induced obesity, we investigated the development of HFD-induced obesity in mice with and without PCM supplementation for 6 weeks and measured the effects of PCM on serum lipid profiles such as TG, TC, HDL-cholesterol, and LDL-cholesterol at the experimental end. [Table 1](#tab1){ref-type="table"} shows the body weight change and visceral fat weight during the experimental periods. As shown in [Table 1](#tab1){ref-type="table"}, HFD control mice increased significantly final body weight compared with normal mice (55.15 ± 1.78 g, 47.92 ± 1.46 g, resp., *p* \< 0.01). In addition, the visceral fat weight in HFD control mice was significantly increased compared to normal mice (238% of normal value), but orlistat and PCM200-treated mice were significantly decreased compared with those of HFD control mice. PCM50 treatment showed a tendency to decrease (without significance). Above all, body weight change reduced significantly in all drug-treated experimental groups. Overall, PCM may help to improve the disorders of HFD-induced obesity. Besides, [Figure 3](#fig3){ref-type="fig"} showed that high-fat diets caused a marked increase in serum TG, TC, and LDL-cholesterol (*p* \< 0.05, *p* \< 0.01, and *p* \< 0.05, resp., except HDL-cholesterol). The augmented TG, TC, and LDL-cholesterol levels were significantly lowered by orlistat and PCM200 treatment compared with the HFD control mice, whereas the administration of orlistat and PCM slightly elevated the HDL level (without significance).

4. Conclusion {#sec4}
=============

The present study conducted how PCM exerts antiobesity effect related to antioxidant and pancreatic lipase activities. Taken together, PCM inhibited triglyceride absorption via the inhibition of pancreatic lipase and had preventive effects on suppressing serum lipid parameters and visceral fat accumulation in HFD-fed obese mice. These results suggest that PCM administration may attenuate some of the physiological changes that occur in obesity.
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![DPPH radical scavenging activity (a, b) and ABTS radical scavenging activity (c, d). (a, c) Ascorbic acid and (b, d) PCM,*Diospyros kaki* fruit and*Citrus unshiu* peel mixture extract. Each experiment was run in triplicate. The ascorbic acid was used as standard sample.](BMRI2016-1723042.001){#fig1}

![Inhibition of pancreatic lipase by PCM. Orlistat was used as positive control. PCM,*Diospyros kaki* fruit and*Citrus unshiu* peel mixture extract.](BMRI2016-1723042.002){#fig2}

![Serum triglyceride, total cholesterol, HDL-cholesterol, and LDL-cholesterol levels. Con, HFD control mice; O, orlistat 60 mg/kg-treated and HFD-fed mice; PCM50, PCM 50 mg/kg-treated and HFD-fed mice. PCM200, PCM 200 mg/kg-treated and HFD-fed mice. Data are the mean ± SEM, *n* = 8. Significance: ^*∗*^ *p* \< 0.05 and ^*∗∗*^ *p* \< 0.01 versus HFD control mice.](BMRI2016-1723042.003){#fig3}

###### 

The effect of PCM on body weight and visceral fat weight.

  Group          Body weight    Visceral fat weight                       
  -------------- -------------- --------------------- ------------------- -------------------
  Normal         36.06 ± 0.96   47.92 ± 1.46^*∗∗*^    11.86 ± 1.00^*∗*^   24.1 ± 1.0^*∗∗∗*^
  HFD-fed mice                                                             
   Con           37.67 ± 0.51   55.15 ± 1.78          17.48 ± 1.95        57.5 ± 1.5
   O             36.71 ± 0.96   44.92 ± 1.62^*∗∗*^    8.21 ± 1.82^*∗∗*^   42.5 ± 2.8^*∗*^
   PCM50         37.18 ± 0.44   48.06 ± 0.17^*∗∗*^    10.88 ± 0.52^*∗*^   50.6 ± 3.2
   PCM200        36.93 ± 0.38   45.98 ± 0.94^*∗∗*^    9.05 ± 0.90^*∗∗*^   50.3 ± 2.3^*∗*^

Con, HFD control mice; O, orlistat 60 mg/kg-treated and HFD-fed mice; PCM50, PCM 50 mg/kg-treated and HFD-fed mice.

PCM 200, PCM 200 mg/kg-treated and HFD-fed mice. Data are the mean ± SEM, *n* = 8.

Significance: ^*∗*^ *p* \< 0.05, ^*∗∗*^ *p* \< 0.01, and ^*∗∗∗*^ *p* \< 0.001 versus HFD control mice.
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